At the end of the latest market close, Jazz Pharmaceuticals plc (JAZZ) was valued at $153.21. In that particular session, Stock kicked-off at the price of $153.09 while reaching the peak value of $153.905 and lowest value recorded on the day was $150.75. The stock current value is $151.26.Recently in News on November 18, 2022, Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). Rylaze dosing options provide sustained asparaginase activity throughout the entire course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. You can read further details here
Jazz Pharmaceuticals plc had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $169.98 on 04/07/22, with the lowest value was $125.36 for the same time period, recorded on 09/27/22.
Jazz Pharmaceuticals plc (JAZZ) full year performance was 16.76%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Jazz Pharmaceuticals plc shares are logging -11.01% during the 52-week period from high price, and 28.58% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $117.64 and $169.98.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 341355 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Jazz Pharmaceuticals plc (JAZZ) recorded performance in the market was 18.73%, having the revenues showcasing -5.76% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 9.39B, as it employees total of 3200 workers.
Market experts do have their say about Jazz Pharmaceuticals plc (JAZZ)
During the last month, 14 analysts gave the Jazz Pharmaceuticals plc a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 147.65, with a change in the price was noted -8.78. In a similar fashion, Jazz Pharmaceuticals plc posted a movement of -5.49% for the period of last 100 days, recording 511,065 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for JAZZ is recording 2.09 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.07.
Technical breakdown of Jazz Pharmaceuticals plc (JAZZ)
Raw Stochastic average of Jazz Pharmaceuticals plc in the period of last 50 days is set at 84.42%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 71.57%. In the last 20 days, the company’s Stochastic %K was 74.13% and its Stochastic %D was recorded 68.87%.
Bearing in mind the latest performance of Jazz Pharmaceuticals plc, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 18.73%. Additionally, trading for the stock in the period of the last six months notably improved by 2.20%, alongside a boost of 16.76% for the period of the last 12 months. The shares increased approximately by 5.97% in the 7-day charts and went down by 9.91% in the period of the last 30 days. Common stock shares were lifted by -5.76% during last recorded quarter.